US Edition
Early treatment with Natalizumab.
Summary by Multiple Sclerosis Research Blog
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Early treatment with Natalizumab.
Tweet European Association of Neurology Meeting Sirito T et al. EPO-288 | Optimizing rapid inflammation controland risk management in highly active multiple sclerosis:The role of natalizumabBackground and aims: The rapid initiation of disease modifying therapies (DMTs) in patients with Highly Active Multiple Sclerosis (HAMS) facilitates prompt suppression of inflammatory activity. However, this approach requires a careful balance between efficac…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
